"Strange days have found us. Strange days have tracked us down," Jim Morrison sang in 1967.
Nearly 50 years later, it would appear that things can only get weirder.
President-elect Donald Trump hasn't even been sworn in yet and already he is issuing edicts that have sent the world and markets scrambling. Every day, it would seem that another country, industry or person has been subject to his Twitter ire.
Wednesday's revelation was another shocker.
"I'm going to bring down drug prices. I don't like what's happened with drug prices," Trump said in an interview published on Time magazine's website.
These words immediately drove down biotechnology stocks.
After all, it was Hillary Clinton who was supposedly the anti-pharmaceutical industry candidate. Her remarks criticizing the pricing practices of Mylan and Valeant Pharmaceuticals sent their stocks into a tailspin this year.
When Trump won the presidential election, the industry rallied.
Not everyone in the the sector is surprised.
Last week, Brent Saunders, chief executive of Allergan warned that a Trump presidency could prove to be more "vicious" than Clinton toward pharmaceutical pricing.
Allergan is a holding in Jim Cramer's Action Alerts PLUS Charitable Trust Portfolio. See how Cramer rates the stock here. Want to be alerted before Cramer buys or sells AGN? Learn more now.
Although Trump's plans are still not clear, it is likely that he will continue with this populist tack and perhaps even turn into an anti-drug price increase crusader.
That leaves many drug makers in a tight spot. However, perhaps none are as dangerous for investors as Mylan.
Mylan is the maker of EpiPens, personal medical devices that deliver lifesaving doses of epinephrine to patients suffering from acute asthma attacks and anaphylactic shock.